Inhibition of PDE5 Restores Depressed Baroreflex Sensitivity in Renovascular Hypertensive Rats

Renal artery stenosis is frequently associated with resistant hypertension, which is defined as failure to normalize blood pressure (BP) even when combined drugs are used. Inhibition of PDE5 by sildenafil has been shown to increase endothelial function and decrease blood pressure in experimental models. However, no available study evaluated the baroreflex sensitivity nor autonomic balance in renovascular hypertensive rats treated with sildenafil. In a translational medicine perspective, our hypothesis is that sildenafil could improve autonomic imbalance and baroreflex sensitivity, contributing to lower blood pressure. Renovascular hypertensive 2-kidney-1-clip (2K1C) and sham rats were treated with sildenafil (45 mg/Kg/day) during 7 days. At the end of treatment, BP and heart rate (HR) were recorded in conscious rats after a 24-h-recovery period. Spontaneous and drug-induced baroreflex sensitivity and autonomic tone were evaluated; in addition, lipid peroxidation was measured in plasma samples. Treatment was efficient in increasing both spontaneous and induced baroreflex sensitivity in treated hypertensive animals. Inhibition of PDE5 was also capable of ameliorating autonomic imbalance in 2K1C rats and decreasing systemic oxidative stress. Taken together, these beneficial effects resulted in significant reductions in BP without affecting HR. We suggest that sildenafil could be considered as a promising alternative to treat resistant hypertension.

[1]  D. Cicchetti,et al.  Clinical Significance , 2020, Encyclopedia of Autism Spectrum Disorders.

[2]  B. Nogueira,et al.  Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension. , 2015, Current pharmaceutical biotechnology.

[3]  Á. Gava,et al.  Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: the beneficial effects of sildenafil. , 2015, Current pharmaceutical biotechnology.

[4]  Guido Grassi,et al.  The sympathetic nervous system alterations in human hypertension. , 2015, Circulation research.

[5]  S. Oparil,et al.  New approaches in the treatment of hypertension. , 2015, Circulation research.

[6]  V. Braga,et al.  Coconut oil supplementation and physical exercise improves baroreflex sensitivity and oxidative stress in hypertensive rats. , 2015, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[7]  D. Casarini,et al.  Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension , 2014, Journal of Translational Medicine.

[8]  W. Vongpatanasin.  Resistant hypertension: a review of diagnosis and management. , 2014, JAMA.

[9]  D. Casarini,et al.  Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension , 2014, Journal of Translational Medicine.

[10]  J. Tanus-Santos,et al.  Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension , 2013, Redox biology.

[11]  D. Koesling,et al.  Phosphodiesterase 5 Attenuates the Vasodilatory Response in Renovascular Hypertension , 2013, PloS one.

[12]  Kavaljit H. Chhabra,et al.  Brain Angiotensin-Converting Enzyme Type 2 Shedding Contributes to the Development of Neurogenic Hypertension , 2013, Circulation research.

[13]  Thiago M. C. Pereira,et al.  Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis , 2013, Lipids in Health and Disease.

[14]  C. Bergamaschi,et al.  Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension. , 2013, American journal of hypertension.

[15]  B. Phillips,et al.  Sildenafil increases sympathetically mediated vascular tone in humans. , 2013, American journal of hypertension.

[16]  T. M. de Queiroz,et al.  Angiotensin-II-derived reactive oxygen species on baroreflex sensitivity during hypertension: new perspectives , 2013, Front. Physiol..

[17]  F. Messerli,et al.  Blood pressure and diabetes: vicious twins , 2013, Heart.

[18]  杜昕,et al.  Resistant hypertension , 2013 .

[19]  A. Ferreira,et al.  Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. , 2013, The Journal of endocrinology.

[20]  Á. Gava,et al.  Sildenafil restores endothelial function in the apolipoprotein E knockout mouse , 2013, Journal of Translational Medicine.

[21]  Á. Gava,et al.  Cardiac-Autonomic Imbalance and Baroreflex Dysfunction in the Renovascular Angiotensin-Dependent Hypertensive Mouse , 2012, International journal of hypertension.

[22]  V. Braga,et al.  α-Lipoic Acid Reduces Hypertension and Increases Baroreflex Sensitivity in Renovascular Hypertensive Rats , 2012, Molecules.

[23]  V. Braga,et al.  Quercetin Improves Baroreflex Sensitivity in Spontaneously Hypertensive Rats , 2012, Molecules.

[24]  K. Sunagawa,et al.  Different role of oxidative stress in paraventricular nucleus and rostral ventrolateral medulla in cardiovascular regulation in awake spontaneously hypertensive rats , 2012, Journal of hypertension.

[25]  Y. Hirooka,et al.  Oxidative stress in the brain causes hypertension via sympathoexcitation , 2012, Front. Physio..

[26]  V. Braga,et al.  Scavenging of NADPH oxidase‐derived superoxide anions improves depressed baroreflex sensitivity in spontaneously hypertensive rats , 2012, Clinical and experimental pharmacology & physiology.

[27]  K. Sunagawa,et al.  Oxidative stress in the rostral ventrolateral medulla modulates excitatory and inhibitory inputs in spontaneously hypertensive rats , 2012, Journal of hypertension.

[28]  V. Braga,et al.  Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. , 2011, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[29]  H. Salgado,et al.  Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration , 2011, Clinics.

[30]  V. Papademetriou,et al.  Common Secondary Causes of Resistant Hypertension and Rational for Treatment , 2011, International journal of hypertension.

[31]  E. Colombari,et al.  Central antioxidant therapy inhibits parasympathetic baroreflex control in conscious rats , 2011, Neuroscience Letters.

[32]  M. Dolnikoff,et al.  The role of oxidative stress in renovascular hypertension , 2011, Clinical and experimental pharmacology & physiology.

[33]  V. Braga,et al.  Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats , 2011, Autonomic Neuroscience.

[34]  I. Eardley,et al.  An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction , 2010, Nature Reviews Urology.

[35]  V. Braga,et al.  Superoxide scavenging in the rostral ventrolateral medulla blunts the pressor response to peripheral chemoreflex activation , 2010, Brain Research.

[36]  E. Nishi,et al.  Vitamin C prevents DNA damage induced by renovascular hypertension in multiple organs of Wistar rats , 2010, Human & experimental toxicology.

[37]  C. Bergamaschi,et al.  Chronic antioxidant treatment improves arterial renovascular hypertension and oxidative stress markers in the kidney in Wistar rats. , 2010, American journal of hypertension.

[38]  D. Laude,et al.  Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients , 2009, Diabetes/metabolism research and reviews.

[39]  S. Biswal,et al.  Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. , 2009, The Journal of urology.

[40]  R. Davisson,et al.  Cardiovascular responses to peripheral chemoreflex activation and comparison of different methods to evaluate baroreflex gain in conscious mice using telemetry. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[41]  S. Kenawy,et al.  Sildenafil augments the beneficial hemodynamic and histopathological effects of amlodipine in nitric oxide-deficient hypertensive rats: role of nitric oxide-cyclic GMP pathway. , 2008, Pharmacological research.

[42]  C. Silva,et al.  Sildenafil acts on the central nervous system increasing sympathetic activity. , 2008, Journal of applied physiology.

[43]  G. Ertl,et al.  Improvement of vascular function by acute and chronic treatment with the PDE‐5 inhibitor sildenafil in experimental diabetes mellitus , 2008, British journal of pharmacology.

[44]  M. Guazzi,et al.  Sildenafil reduces L‐NAME‐induced severe hypertension and worsening of myocardial ischaemia–reperfusion damage in the rat , 2007, British journal of pharmacology.

[45]  D. Webb,et al.  Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension , 2006, Hypertension.

[46]  L. Ghiadoni,et al.  Phosphodiesterase 5 inhibition to treat essential hypertension: is this the beginning of the story? , 2006, Hypertension.

[47]  J. Tanus-Santos,et al.  Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. , 2006, European journal of pharmacology.

[48]  F. Abboud,et al.  Baroreceptor reflex sensitivity estimated by the sequence technique is reliable in rats. , 2006, American journal of physiology. Heart and circulatory physiology.

[49]  R. Persad,et al.  Sildenafil inhibits the formation of superoxide and the expression of gp47phox NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells , 2005, BJU international.

[50]  G. Angelini,et al.  Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. , 2005, European journal of pharmacology.

[51]  S. Raja,et al.  Sildenafil: emerging cardiovascular indications. , 2004, The Annals of thoracic surgery.

[52]  R. Touyz.  Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? , 2004, Hypertension.

[53]  A. Takeshita,et al.  Overexpression of eNOS in the RVLM Causes Hypotension and Bradycardia Via GABA Release , 2001, Hypertension.

[54]  M. Irigoyen,et al.  Baroreflex control of sympathetic activity in experimental hypertension. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[55]  K. Mitchell,et al.  Unraveling the Mystery of Goldblatt Hypertension. , 1998, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[56]  H. Rosolová.  [New approaches in the treatment of hypertension in metabolic diseases]. , 1998, Casopis lekaru ceskych.

[57]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[58]  H. Goldblatt,et al.  STUDIES ON EXPERIMENTAL HYPERTENSION I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA , 1934 .

[59]  R. Carey.  Resistant hypertension. , 2013, Hypertension.

[60]  D. M.,et al.  SYMPATHETIC NERVOUS , 2006 .

[61]  J. Corbin,et al.  Phosphodiesterase-5 Inhibition , 2004 .

[62]  M. Ito,et al.  [Sildenafil (Viagra)]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[63]  P. Wright,et al.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[64]  J. Sahade.  The beginning of the story , 1996 .

[65]  R. Souhami.  New approaches to treatment , 1985 .